Home
       
STOCK MARKETS


Back

Corporate Information
  • Company Presentation
  • Business Segments
  • Strategy & Goals
  • President’s Message
  • Year in Brief
  • Management
  • Subsidiaries
  • Acquisitions & Divestments
  • Addresses
    News & Reports
  • Reports
  • Presentations
  • Press releases
    Financial Information
  • Financial Summary
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Illustrations
    Shareholder Information
  • Shareholders
  • Shares & Dividends
  • Annual General Meeting
  • Financial Calendar
     
       

    Embla Medical hf

    http://www.ossur.com
    Embla Medical hf
    Grjothals 5
    110 Reykjavik
    ICELAND
    Tel: ‎+ 354 515 1300
    Fax: ‎+ 354 515 1366
    E-mail: mail@ossur.com

    Print this page Print this page    Send to a Friend E-mail this page to your friend    Disclaimer
    Press releases  

    2011-07-28 20:42:07

    Össur - Second Quarter Report 2011

    Össur - Second Quarter Report 2011

    RECORD SALES IN THE SECOND QUARTER

    Sales - The second quarter delivered record sales above USD 100 million and 17% sales growth, measured in USD. Sales increased by 10% measured in local currency. All regions and segments contribute to the growth. Total sales amounted to USD 105 million compared to USD 90 million in the second quarter of 2010. Success in bracing and supports in Americas continues while bracing and supports sales in EMEA was weak in the quarter. Overall sales growth of bracing and supports was 16%, measured in local currency. Sales in prosthetics increased by 4% measured in local currency.

    Profitability - Consolidation of manufacturing operations impacted profitability in the quarter. EBITDA amounted to USD 20 million or 19% of sales and gross profit amounted to USD 63 million or 60% of sales. Net profit amounted to USD 10 million or 10% of sales.

    Jón Sigurðsson, President & CEO, comments:

    "The second quarter results are overall good and in line with our guidance for the year. All product segments show decent growth and some markets delivered excellent performance. We continue to gain market share in the bracing and supports segment in Americas, our largest market, and the prosthetics segment in EMEA shows excellent performance across all product segments and regions."

    Highlights of the quarter:

    • Stable flow of new products - Össur's product pipeline has been strong and the healthy flow of new products has been an important contributor to the Company's growth. In the second quarter five new products were launched, two in the bracing and supports segment and three in the prosthetics segment.
    • Consolidation of manufacturing - One of the most important projects in 2011 is focus on consolidation of manufacturing operations. The new manufacturing facility in Mexico for bracing and supports is progressing well and during 2011 all bracing and supports manufacturing in the US will be moved to the Mexico facility.

    Guidance 2011 - Management maintains estimates of local currency organic sales growth for 2011 in the range of 4-6%. Adjusted EBITDA ratio is estimated to be in the range of 20-21% of sales for the year, as reported in the 2010 full year report.


    Conference call tomorrow 29 July at 12:00 CET/ 10:00 GMT/ 6:00 EDT

    Tomorrow, Friday 29 July 2011 Jón Sigurðsson, President and CEO, and Hjörleifur Pálsson, CFO, will host a conference call for investors, analysts and shareholders presenting and discussing the results of the second quarter of 2011. The conference call will be conducted in English and can be heard on Össur's website: www.ossur.com

    To participate in the meeting please call one of the following telephone numbers:
    Europe: +44 (0)20 3043 2436 or +46 (0)8 505 598 53
    The United States: +1 866 458 40 87
    Iceland: 800 8660




    This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

    The owner of this announcement warrants that:
    (i) the releases contained herein are protected by copyright and other applicable laws; and
    (ii) they are solely responsible for the content, accuracy and originality of the
    information contained therein.

    Source: Ossur Hf via Thomson Reuters ONE

    HUG#1534637



     
    Back
     
     
       Privacy Policy | Disclaimer | Set this page as your homepage| © Euroland.com 2000-2024